2
RESEARCH METHODOLOGY
39
5
MARKET OVERVIEW
AI-driven clinical trials are transforming patient recruitment, compliance, and data management amidst regulatory challenges.
64
5.3.1.1
INCREASING DEMAND FOR PERSONALIZED TREATMENTS
5.3.1.2
SUPPORT FOR DECENTRALIZED AND GLOBAL TRIALS
5.3.1.3
REGULATORY COMPLIANCE AND ETHICAL CONSIDERATIONS
5.3.1.4
AUTOMATED DOCUMENT REVIEW FOR BETTER REGULATORY COMPLIANCE
5.3.1.5
FOCUS ON REAL-TIME DATA MANAGEMENT AND ANALYSIS
5.3.2.1
DATA PRIVACY AND SECURITY CONCERNS
5.3.2.2
INTEGRATION CHALLENGES WITH LEGACY SYSTEMS AND RESISTANCE FROM HEALTHCARE PROFESSIONALS
5.3.2.3
HIGH IMPLEMENTATION COST AND NEED FOR SKILLED AI PROFESSIONALS
5.3.3.1
USE OF PREDICTIVE ANALYTICS IN CLINICAL TRIALS
5.3.3.2
DEVELOPMENT OF VIRTUAL CONTROL ARMS FOR FASTER TRIALS
5.3.3.3
INTEGRATING NATURAL LANGUAGE PROCESSING INTO CLINICAL TRIALS FOR DATA EXTRACTION
5.3.4.1
ADDRESSING ALGORITHM BIAS AND FAIRNESS
5.3.4.2
INSUFFICIENT TECHNICAL EXPERTISE IN AI-BASED SOLUTIONS
5.4.1
INCREASING ADOPTION OF DECENTRALIZED CLINICAL TRIALS
5.4.2
RISING FOCUS ON AI-POWERED PATIENT RECRUITMENT AND RETENTION
5.6.1
AI-POWERED APPROACH TO OVERCOME CHALLENGES IN IPF DRUG DEVELOPMENT
5.6.2
REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH ADVANCED MATCHING NETWORKS
5.6.3
BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS
5.8
PORTER'S FIVE FORCES ANALYSIS
5.8.1
BARGAINING POWER OF SUPPLIERS
5.8.2
BARGAINING POWER OF BUYERS
5.8.3
THREAT OF SUBSTITUTES
5.8.4
THREAT OF NEW ENTRANTS
5.8.5
INTENSITY OF COMPETITIVE RIVALRY
5.9
KEY STAKEHOLDERS & BUYING CRITERIA
5.9.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.9.2
KEY BUYING CRITERIA
5.10
REGULATORY LANDSCAPE
5.10.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.2
REGULATORY FRAMEWORK
5.11.1
PATENT PUBLICATION TRENDS FOR AI IN CLINICAL TRIALS
5.11.2
JURISDICTION AND TOP APPLICANT ANALYSIS
5.12.1.1
MACHINE LEARNING
5.12.1.2
NATURAL LANGUAGE PROCESSING
5.12.2
COMPLEMENTARY TECHNOLOGIES
5.12.2.1
INTERNET OF THINGS
5.12.3
ADJACENT TECHNOLOGIES
5.12.3.1
ADVANCED GENOMICS
5.13.1
INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023
5.13.2
INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022–2024
5.14
KEY CONFERENCES & EVENTS, 2024–2025
5.15
TRENDS AND DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.16
UNMET NEEDS AND END-USER EXPECTATIONS
5.16.2
END-USER EXPECTATIONS
5.17
INVESTMENT & FUNDING SCENARIO
5.18
IMPACT OF AI/GEN AI ON AI IN CLINICAL TRIALS MARKET
5.18.2
IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
5.18.2.2
CLINICAL TRIALS MARKET
5.18.2.3
ECLINICAL SOLUTIONS MARKET
5.18.2.4
AI IN BIOTECHNOLOGY MARKET
5.18.3
USERS READINESS AND IMPACT ASSESSMENT
5.18.3.1.1
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
5.18.3.1.2
CONTRACT RESEARCH ORGANIZATIONS
5.18.3.2
IMPACT ASSESSMENT
5.18.3.2.1
USER A: HEALTHCARE PROVIDERS
5.18.3.2.2
USER B: RESEARCH INSTITUTES & LABORATORIES
6
AI IN CLINICAL TRIALS MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 9 Data Tables
101
6.2.1
COST-EFFECTIVENESS, IMPROVED EFFICIENCY, AND REDUCED HUMAN ERRORS TO DRIVE ADOPTION IN CLINICAL TRIALS
6.3.1
HIGH FAILURE RATES OF CLINICAL TRIALS AND NEED FOR STREAMLINED PROCESSES TO FUEL MARKET GROWTH
6.4.1
NEED TO ACCELERATE DRUG DEVELOPMENT PROCESSES AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH
6.5.1
CONSULTING SERVICES
6.5.1.1
CONSULTING SERVICES TO OPTIMIZE TRIAL DESIGN, ENHANCE PATIENT RECRUITMENT, AND IMPROVE DATA MANAGEMENT
6.5.2
IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
6.5.2.1
NEED FOR SMOOTH INTEGRATION AND OPTIMIZATION OF AI TECHNOLOGIES TO BOOST SEGMENT GROWTH
6.5.3
TRAINING & EDUCATION SERVICES
6.5.3.1
NEED FOR SKILLED TALENT FOR MANAGING COMPLEX AI SYSTEMS TO AUGMENT SEGMENT GROWTH
6.5.4
POST-SALES & MAINTENANCE SERVICES
6.5.4.1
DEVELOPMENT OF COMPLEX AI SYSTEMS AND NEED FOR CONTINUOUS IMPROVEMENT IN AI ALGORITHMS TO DRIVE SEGMENT GROWTH
7
AI IN CLINICAL TRIALS MARKET, BY FUNCTION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 15 Data Tables
111
7.2.1
PATIENT IDENTIFICATION & SCREENING
7.2.1.1
REDUCED PATIENT SCREENING TIME AND BETTER ACCURACY THAN HUMAN CLINICIANS TO DRIVE MARKET
7.2.2
PATIENT ENGAGEMENT & RETENTION
7.2.2.1
BETTER PERSONALIZED COMMUNICATION AND SUPPORT FOR CLINICAL TRIALS TO PROPEL MARKET GROWTH
7.2.3.1
COST-EFFECTIVE AND IMPROVED PARTICIPANT RECRUITMENT AND RETENTION TO FUEL SEGMENT GROWTH
7.3
TRIAL DESIGN OPTIMIZATION
7.3.1
WORKFLOW MANAGEMENT
7.3.1.1
EFFECTIVE REAL-TIME TRACKING, AUTOMATED REPORTING, AND MILESTONE MONITORING TO SPUR SEGMENT GROWTH
7.3.2
PREDICTIVE MODELING
7.3.2.1
ABILITY TO OPTIMIZE TRIAL DESIGN, PREDICT RISKS, AND IDENTIFY EFFECTIVE TREATMENT PROTOCOLS TO DRIVE SEGMENT
7.3.3.1
AI-DRIVEN SOLUTIONS FOR RISK PREDICTION TO IMPROVE PATIENT SAFETY AND DATA INTEGRITY
7.4
DATA MANAGEMENT & QUALITY CONTROL
7.4.1
FOCUS ON MAINTAINING DATA ACCURACY AND INTEGRITY IN CLINICAL TRIALS TO BOOST ADOPTION
7.5
ADVERSE EVENT PREDICTION & DETECTION
7.5.1
MITIGATING RISKS AND HARNESSING AI-DRIVEN ADVERSE EVENT DETECTION TO SPUR MARKET GROWTH
7.6.1
DRUG REPURPOSING TO VALIDATE HYPOTHESES AGAINST REAL-TIME PATIENT DATA IN RARE DISEASES
7.7
REGULATORY COMPLIANCE
7.7.1
COMPLEXITY OF GLOBAL REGULATORY ENVIRONMENTS AND NEED FOR FASTER DRUG APPROVALS TO AID MARKET GROWTH
8
AI IN CLINICAL TRIALS MARKET, BY PHASE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 5 Data Tables
126
8.2
PHASE I CLINICAL TRIALS
8.2.1
FASTER PATIENT IDENTIFICATION AND RECRUITMENT TO PROPEL ADOPTION OF AI
8.3
PHASE II CLINICAL TRIALS
8.3.1
NEED FOR ACCURATE PREDICTION OF OPTIMAL DOSAGE IN PHASE II TRIALS TO BOOST USE OF AI
8.4
PHASE III CLINICAL TRIALS
8.4.1
NEED TO CHECK DRUG EFFICACY AND MONITOR ADVERSE REACTIONS TO AUGMENT MARKET GROWTH
8.5
PHASE IV CLINICAL TRIALS
8.5.1
AI TO ASSESS SAFETY AND LONG-TERM OUTCOMES OF TREATMENT IN LARGER PATIENT POPULATION UNDER PHASE IV TRIALS
9
AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 8 Data Tables
132
9.2
CLOUD-BASED SOLUTIONS
9.2.1
PUBLIC CLOUD-BASED SOLUTIONS
9.2.1.1
REDUCED NEED FOR COSTLY ON-PREMISES INFRASTRUCTURE AND BETTER REGULATORY COMPLIANCE TO FUEL ADOPTION
9.2.2
PRIVATE CLOUD-BASED SOLUTIONS
9.2.2.1
BETTER SECURITY AND PERSONALIZATION FOR SENSITIVE DATA TO PROPEL SEGMENT GROWTH
9.2.3
MULTI CLOUD-BASED SOLUTIONS
9.2.3.1
USE OF ADVANCED PREDICTIVE MODELING FOR PATIENT RECRUITMENT AND SITE PERFORMANCE OPTIMIZATION TO DRIVE MARKET
9.2.4
HYBRID CLOUD-BASED SOLUTIONS
9.2.4.1
BETTER FLEXIBILITY IN DATA MANAGEMENT TO REDUCE RESOURCE REQUIREMENTS IN CLINICAL TRIALS
9.3
ON-PREMISES SOLUTIONS
9.3.1
ON-PREMISES SOLUTIONS TO OFFER SECURE ENVIRONMENT FOR MANAGING SENSITIVE DATA AND RUNNING COMPLEX ALGORITHMS
10
AI IN CLINICAL TRIALS MARKET, BY INDICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 8 Data Tables
140
10.2.1
HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE DRUGS TO DRIVE SEGMENT GROWTH
10.3
NEUROLOGICAL DISEASES
10.3.1
COMPLEXITY OF NEUROGENERATIVE DISORDERS AND SHORTAGE OF DRUGS FOR PARKINSON’S DISEASE TO SPUR MARKET GROWTH
10.4
CARDIOVASCULAR DISEASES
10.4.1
RISING DEMAND FOR NOVEL CARDIOVASCULAR DRUGS TO DRIVE SEGMENT
10.5.1
RISING PREVALENCE OF DIABETES AND OBESITY TO SUPPORT MARKET GROWTH
10.6.1
RECENT EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITIES FOR INFECTIOUS DISEASES
10.7.1
GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
11
AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 12 Data Tables
150
11.2.1.1
REDUCED CHANCE OF ERRORS IN CLINICAL TRIALS AND ENHANCED DATA CONSISTENCY TO AUGMENT SEGMENT GROWTH
11.2.2
SUPERVISED LEARNING
11.2.2.1
SUPERVISED LEARNING TO FOCUS ON EFFECTIVE PATIENT STRATIFICATION, DISEASE PROGRESSION PREDICTION, AND BIOMARKER IDENTIFICATION
11.2.3
UNSUPERVISED LEARNING
11.2.3.1
EFFECTIVE HANDLING OF COMPLEX AND UNSTRUCTURED DATASETS TO AID ADOPTION IN TRIAL DESIGN AND EXECUTION
11.2.4
REINFORCEMENT LEARNING
11.2.4.1
DYNAMIC LEARNING CAPABILITIES TO AID ADOPTION IN PERSONALIZED MEDICINE AND PRECISION ONCOLOGY
11.2.5
OTHER MACHINE LEARNING TECHNOLOGIES
11.3
NATURAL LANGUAGE PROCESSING
11.3.1
ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO PROPEL GROWTH IN TRIAL MANAGEMENT
11.4.1
RISING NEED FOR REPRODUCIBLE ANALYSIS IN CLINICAL ENDPOINTS TO DRIVE MARKET
11.5
ROBOTIC PROCESS AUTOMATION
11.5.1
ROBOTIC PROCESS AUTOMATION TO ENHANCE OPERATIONAL EFFICIENCY BY AUTOMATING ADMINISTRATIVE WORKFLOWS
12
AI IN CLINICAL TRIALS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 5 Data Tables
163
12.2.1
INCREASING INVESTMENTS IN AI-BASED INNOVATION TO AID DEVELOPMENT OF PERSONALIZED HEALTHCARE SOLUTIONS
12.3.1
HIGH PREVALENCE OF GENETIC DISORDERS AND TECHNOLOGICAL ADVANCEMENTS IN CAR-T THERAPIES TO DRIVE GROWTH
12.4
REGENERATIVE MEDICINES
12.4.1
INCREASED NEED FOR PRECISE MONITORING AND ADVANCEMENTS IN STEM CELL RESEARCH TO SPUR MARKET GROWTH
12.5
MEDICAL DEVICES & DIAGNOSTICS
12.5.1
NEED FOR REAL-TIME MONITORING AND REMOTE DATA ACQUISITION DURING TRIALS TO ACCELERATE MARKET GROWTH
13
AI IN CLINICAL TRIALS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 7 Data Tables
169
13.2
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
13.2.1
HIGH R&D INVESTMENTS AND INCREASED REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH
13.3
RESEARCH INSTITUTES & LABORATORIES
13.3.1
INCREASED GOVERNMENT GRANTS AND COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH
13.4
HEALTHCARE PROVIDERS
13.4.1
ADVANCEMENTS IN PRECISION MEDICINES AND NEED FOR REAL-WORLD EVIDENCE IN CLINICAL RESEARCH TO DRIVE MARKET
13.5
CONTRACT RESEARCH ORGANIZATIONS
13.5.1
RISING DEMAND FOR OUTSOURCING CLINICAL TRIAL ACTIVITIES BY PHARMACEUTICAL COMPANIES TO AID MARKET GROWTH
13.6
MEDICAL DEVICE MANUFACTURERS
13.6.1
DEMAND FOR AI-DRIVEN DIAGNOSTICS AND MONITORING DEVICES FOR REMOTE CARE TO PROPEL MARKET GROWTH
14
AI IN CLINICAL TRIALS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 12 Countries | 183 Data Tables.
176
14.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2.1
US TO DOMINATE NORTH AMERICAN AI IN CLINICAL TRIALS MARKET DURING STUDY PERIOD
14.2.3.1
RISING NEED FOR DATA STANDARDIZATION AND INCREASING HEALTH EXPENDITURE TO SUPPORT MARKET GROWTH
14.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
14.3.2.1
HIGH R&D INVESTMENT BY GOVERNMENT ORGANIZATIONS TO AUGMENT MARKET GROWTH
14.3.3.1
INCREASED FOCUS ON RESEARCH ACTIVITIES AND STRATEGIC DEVELOPMENTS BY PHARMA & BIOTECH COMPANIES TO DRIVE MARKET
14.3.4.1
STRONG GOVERNMENT SUPPORT AND FOCUS ON DOMESTIC DRUG RESEARCH TO PROPEL MARKET GROWTH
14.3.5.1
INCREASED R&D INVESTMENTS FROM PHARMACEUTICAL COMPANIES AND REDUCED TIME FOR DRUG APPROVALS TO FUEL MARKET GROWTH
14.3.6.1
INCREASED TECHNOLOGICAL INVESTMENTS BY PRIVATE ORGANIZATIONS AND INTEGRATED HEALTHCARE SYSTEMS TO SPUR MARKET GROWTH
14.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2.1
WELL-ESTABLISHED CLINICAL TRIAL INFRASTRUCTURE AND ADVANCED BIOMEDICAL RESEARCH TO SUPPORT MARKET GROWTH
14.4.3.1
LOW COST OF CLINICAL TRIALS AND AVAILABILITY OF TREATMENT-NAÏVE POPULATION TO PROPEL MARKET GROWTH
14.4.4.1
FAVORABLE GOVERNMENT POLICIES AND HIGH R&D EXPENDITURE BY INDIAN PHARMACEUTICAL COMPANIES TO SPUR MARKET GROWTH
14.4.5
REST OF ASIA PACIFIC
14.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2.1
INCREASING GOVERNMENTAL SUPPORT FOR INNOVATION AND GROWING BIOTECHNOLOGY SECTOR TO DRIVE MARKET
14.5.3.1
STRONG TECHNOLOGICAL AND RESEARCH CAPABILITIES IN AI APPLICATIONS TO FUEL MARKET GROWTH
14.5.4
REST OF LATIN AMERICA
14.6
MIDDLE EAST & AFRICA
14.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
14.6.2.1
TECHNOLOGICAL INNOVATIONS AND FOCUS ON PRECISION MEDICINES TO AUGMENT MARKET GROWTH
14.6.3
REST OF MIDDLE EAST & AFRICA
15
COMPETITIVE LANDSCAPE
Uncover key player strategies driving AI innovation in clinical trials and market dominance.
279
15.2
KEY PLAYER STRATEGY/RIGHT TO WIN
15.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET
15.3
REVENUE ANALYSIS, 2019–2023
15.4
MARKET SHARE ANALYSIS, 2023
15.4.1
RANKING OF KEY MARKET PLAYERS
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2023
15.5.5.1
COMPANY FOOTPRINT
15.5.5.2
REGION FOOTPRINT
15.5.5.3
OFFERING FOOTPRINT
15.5.5.4
FUNCTION FOOTPRINT
15.5.5.5
END-USER FOOTPRINT
15.6
COMPANY EVALUATION QUADRANT: STARTUP/SMES, 2023
15.6.1
PROGRESSIVE COMPANIES
15.6.2
RESPONSIVE COMPANIES
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
15.7
COMPANY EVALUATION & FINANCIAL METRICS
15.8
BRAND/PRODUCT COMPARISON
15.9
COMPETITIVE SCENARIO
15.9.1
PRODUCT/SERVICE/SOLUTION LAUNCHES
15.9.3
OTHER DEVELOPMENTS
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
301
16.1.1.1
PRODUCTS/SERVICES/SOLUTIONS OFFERED
16.1.1.2
RECENT DEVELOPMENTS
16.1.1.2.1
SOLUTION LAUNCHES
16.1.1.3.2
STRATEGIC CHOICES
16.1.1.3.3
WEAKNESSES & COMPETITIVE THREATS
16.1.2
DASSAULT SYSTÈMES (MEDIDATA)
16.1.5
NVIDIA CORPORATION
16.1.15
MEDIAN TECHNOLOGIES
16.1.16
LANTERN PHARMA INC.
16.1.17
CITELINE, A NORSTELLA COMPANY
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3
CUSTOMIZATION OPTIONS
TABLE 1
AI IN CLINICAL TRIALS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
AI IN CLINICAL TRIALS MARKET: STUDY ASSUMPTIONS
TABLE 3
AI IN CLINICAL TRIALS MARKET: RISK ASSESSMENT
TABLE 4
AI IN CLINICAL TRIALS MARKET: IMPACT ANALYSIS
TABLE 5
CASE STUDY 1: AI-POWERED APPROACH TO OVERCOME CHALLENGES IN IPF DRUG DEVELOPMENT
TABLE 6
CASE STUDY 2: REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH ADVANCED MATCHING NETWORKS
TABLE 7
CASE STUDY 3: BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS
TABLE 8
AI IN CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES
TABLE 9
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
TABLE 10
KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 11
LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
NORTH AMERICA: REGULATORY FRAMEWORK
TABLE 13
EUROPE: REGULATORY FRAMEWORK
TABLE 14
ASIA PACIFIC: REGULATORY FRAMEWORK
TABLE 15
MIDDLE EAST & AFRICA: REGULATORY FRAMEWORK
TABLE 16
LATIN AMERICA: REGULATORY FRAMEWORK
TABLE 17
AI IN CLINICAL TRIALS MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2023–2024
TABLE 18
INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023
TABLE 19
INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022–2024
TABLE 20
AI IN CLINICAL TRIALS MARKET: KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025
TABLE 21
AI IN CLINICAL TRIALS MARKET: UNMET NEEDS
TABLE 22
AI IN CLINICAL TRIALS MARKET: END-USER EXPECTATIONS
TABLE 23
AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 24
AI IN CLINICAL TRIALS MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 25
AI IN CLINICAL TRIALS MARKET FOR NICHE SOLUTIONS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 26
AI IN CLINICAL TRIALS MARKET FOR TECHNOLOGY PROVIDERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 27
AI IN CLINICAL TRIALS MARKET FOR SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 28
CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 29
IMPLEMENTATION SERVICES & OUTGOING IT SUPPORT MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 30
TRAINING & EDUCATION SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 31
POST-SALES & MAINTENANCE SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 32
AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 33
AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY TYPE, 2022–2030 (USD MILLION)
TABLE 34
AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 35
PATIENT IDENTIFICATION & SCREENING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 36
PATIENT ENGAGEMENT & RETENTION MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 37
SITE OPTIMIZATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 38
AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY TYPE, 2022–2030 (USD MILLION)
TABLE 39
AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 40
AI IN CLINICAL TRIALS MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 41
AI IN CLINICAL TRIALS MARKET FOR PREDICTIVE MODELING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 42
AI IN CLINICAL TRIALS MARKET FOR RISK MANAGEMENT, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 43
AI IN CLINICAL TRIALS MARKET FOR DATA MANAGEMENT & QUALITY CONTROL, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 44
AI IN CLINICAL TRIALS MARKET FOR ADVERSE EVENT PREDICTION & DETECTION, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 45
AI IN CLINICAL TRIALS MARKET FOR DRUG REPURPOSING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 46
AI IN CLINICAL TRIALS MARKET FOR REGULATORY COMPLIANCE, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 47
AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 48
AI IN PHASE 1 CLINICAL TRIALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 49
AI IN PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 50
AI IN PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 51
AI IN PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 52
AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 53
AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2030 (USD MILLION)
TABLE 54
AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 55
PUBLIC CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 56
PRIVATE CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 57
MULTI CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 58
HYBRID CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 59
AI IN CLINICAL TRIALS MARKET FOR ON-PREMISES SOLUTIONS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 60
AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 61
AI IN CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 62
AI IN CLINICAL TRIALS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 63
AI IN CLINICAL TRIALS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 64
AI IN CLINICAL TRIALS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 65
AI IN CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 66
AI IN CLINICAL TRIALS MARKET FOR IMMUNOLOGY DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 67
AI IN CLINICAL TRIALS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 68
AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 69
AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
TABLE 70
AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 71
DEEP LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 72
SUPERVISED LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 73
UNSUPERVISED LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 74
REINFORCEMENT LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 75
OTHER MACHINE LEARNING TECHNOLOGIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 76
AI IN CLINICAL TRIALS MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 77
AI IN CLINICAL TRIALS MARKET FOR COMPUTER VISION, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 78
AI IN CLINICAL TRIALS MARKET FOR ROBOTIC PROCESS AUTOMATION, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 79
AI IN CLINICAL TRIALS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 80
AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 81
AI IN CLINICAL TRIALS MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 82
AI IN CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 83
AI IN CLINICAL TRIALS MARKET FOR REGENERATIVE MEDICINES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 84
AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICES & DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 85
AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 86
AI IN CLINICAL TRIALS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 87
AI IN CLINICAL TRIALS MARKET FOR RESEARCH INSTITUTES & LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 88
AI IN CLINICAL TRIALS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 89
RECENT ACQUISITIONS /COLLABORATIONS WITH CONTRACT RESEARCH ORGANIZATIONS
TABLE 90
AI IN CLINICAL TRIALS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 91
AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 92
AI IN CLINICAL TRIALS MARKET, BY REGION, 2022–2030 (USD MILLION)
TABLE 93
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 94
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 95
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 96
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 97
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 98
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 99
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 100
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 101
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 102
US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
TABLE 103
US: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 104
US: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 105
US: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 106
US: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 107
US: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 108
US: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 109
US: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 110
US: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 111
CANADA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 112
CANADA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 113
CANADA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 114
CANADA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 115
CANADA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 116
CANADA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 117
CANADA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 118
CANADA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 119
EUROPE: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 120
EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 121
EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 122
EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 123
EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 124
EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 125
EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 126
EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 127
EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 128
UK: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 129
UK: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 130
UK: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 131
UK: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 132
UK: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 133
UK: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 134
UK: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 135
UK: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 136
GERMANY: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 137
GERMANY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 138
GERMANY: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 139
GERMANY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 140
GERMANY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 141
GERMANY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 142
GERMANY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 143
GERMANY: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 144
FRANCE: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 145
FRANCE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 146
FRANCE: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 147
FRANCE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 148
FRANCE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 149
FRANCE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 150
FRANCE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 151
FRANCE: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 152
ITALY: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 153
ITALY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 154
ITALY: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 155
ITALY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 156
ITALY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 157
ITALY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 158
ITALY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 159
ITALY: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 160
SPAIN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 161
SPAIN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 162
SPAIN: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 163
SPAIN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 164
SPAIN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 165
SPAIN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 166
SPAIN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 167
SPAIN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 168
REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 169
REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 170
REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 171
REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 172
REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 173
REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 174
REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 175
REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 176
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 177
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 178
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 179
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 180
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 181
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 182
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 183
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 184
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 185
JAPAN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 186
JAPAN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 187
JAPAN: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 188
JAPAN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 189
JAPAN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 190
JAPAN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 191
JAPAN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 192
JAPAN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 193
CHINA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 194
CHINA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 195
CHINA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 196
CHINA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 197
CHINA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 198
CHINA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 199
CHINA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 200
CHINA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 201
INDIA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 202
INDIA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 203
INDIA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 204
INDIA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 205
INDIA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 206
INDIA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 207
INDIA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 208
INDIA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 209
REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 210
REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 211
REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 212
REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 213
REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 214
REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 215
REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 216
REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 217
LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 218
LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 219
LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 220
LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 221
LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 222
LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 223
LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 224
LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 225
LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 226
BRAZIL: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 227
BRAZIL: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 228
BRAZIL: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 229
BRAZIL: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 230
BRAZIL: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 231
BRAZIL: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 232
BRAZIL: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 233
BRAZIL: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 234
MEXICO: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 235
MEXICO: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 236
MEXICO: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 237
MEXICO: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 238
MEXICO: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 239
MEXICO: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 240
MEXICO: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 241
MEXICO: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 242
REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 243
REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 244
REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 245
REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 246
REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 247
REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 248
REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 249
REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 250
MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY REGION, 2022–2030 (USD MILLION)
TABLE 251
MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 252
MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 253
MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 254
MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 255
MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 256
MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 257
MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 258
MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 259
GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 260
GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 261
GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 262
GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 263
GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 264
GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 265
GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 266
GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 267
REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)
TABLE 268
REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)
TABLE 269
REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)
TABLE 270
REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 271
REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 272
REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
TABLE 273
REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)
TABLE 274
REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 275
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET
TABLE 276
AI IN CLINICAL TRIALS MARKET: DEGREE OF COMPETITION
TABLE 277
AI IN CLINICAL TRIALS MARKET: REGION FOOTPRINT
TABLE 278
AI IN CLINICAL TRIALS MARKET: OFFERING FOOTPRINT
TABLE 279
AI IN CLINICAL TRIALS MARKET: FUNCTION FOOTPRINT
TABLE 280
AI IN CLINICAL TRIALS MARKET: END-USER FOOTPRINT
TABLE 281
AI IN CLINICAL TRIALS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 282
AI IN CLINICAL TRIALS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 283
AI IN CLINICAL TRIALS MARKET: PRODUCT/SERVICE/SOLUTION LAUNCHES, JANUARY 2021–NOVEMBER 2024
TABLE 284
AI IN CLINICAL TRIALS MARKET: DEALS, JANUARY 2021– NOVEMBER 2024
TABLE 285
AI IN CLINICAL TRIALS MARKET: OTHER DEVELOPMENTS, JANUARY 2021– NOVEMBER 2024
TABLE 286
IQVIA INC.: COMPANY OVERVIEW
TABLE 287
IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 288
IQVIA INC.: SOLUTION LAUNCHES, JANUARY 2021–NOVEMBER 2024
TABLE 289
IQVIA INC.: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 290
DASSAULT SYSTÈMES (MEDIDATA): COMPANY OVERVIEW
TABLE 291
DASSAULT SYSTÈMES (MEDIDATA): PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 292
DASSAULT SYSTÈMES (MEDIDATA): SOLUTION LAUNCHES, JANUARY 2021– NOVEMBER 2024
TABLE 293
DASSAULT SYSTÈMES (MEDIDATA): DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 294
INSILICO MEDICINE: COMPANY OVERVIEW
TABLE 295
INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 296
INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024
TABLE 297
TEMPUS AI, INC.: COMPANY OVERVIEW
TABLE 298
TEMPUS AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 299
TEMPUS AI, INC.: SOLUTION LAUNCHES, JANUARY 2021–NOVEMBER 2024
TABLE 300
TEMPUS AI, INC.: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 301
TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024
TABLE 302
NVIDIA CORPORATION: COMPANY OVERVIEW
TABLE 303
NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 304
NVIDIA CORPORATION: PRODUCT AND SERVICE LAUNCHES, JANUARY 2021– NOVEMBER 2024
TABLE 305
NVIDIA CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 306
SAAMA: COMPANY OVERVIEW
TABLE 307
SAAMA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 308
SAAMA: SOLUTION LAUNCHES, JANUARY 2021−NOVEMBER 2024
TABLE 309
SAAMA.: DEALS, JANUARY 2021−NOVEMBER 2024
TABLE 310
PHESI: COMPANY OVERVIEW
TABLE 311
PHESI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 312
PHESI: SOLUTION LAUNCHES, JANUARY 2021−NOVEMBER 2024
TABLE 313
PHESI: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 314
PATHAI, INC.: COMPANY OVERVIEW
TABLE 315
PATHAI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 316
UNLEARN.AI, INC.: COMPANY OVERVIEW
TABLE 317
UNLEARN.AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 318
UNLEARN.AI, INC.: SOLUTION LAUNCHES, JANUARY 2021−NOVEMBER 2024
TABLE 319
UNLEARN.AI, INC.: DEALS, JANUARY 2021−NOVEMBER 2024
TABLE 320
UNLEARN.AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024
TABLE 321
DEEP6.AI: COMPANY OVERVIEW
TABLE 322
DEEP6.AI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 323
DEEP6.AI: SOLUTION LAUNCH, JANUARY 2021−NOVEMBER 2024
TABLE 324
DEEP6.AI: DEALS, JANUARY 2021−NOVEMBER 2024
TABLE 325
MICROSOFT: COMPANY OVERVIEW
TABLE 326
MICROSOFT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 327
MICROSOFT CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 328
IBM: COMPANY OVERVIEW
TABLE 329
IBM: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 330
IBM: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 331
CONCERTAI: COMPANY OVERVIEW
TABLE 332
CONCERTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 333
CONCERTAI: SOLUTION LAUNCHES, JANUARY 2021−NOVEMBER 2024
TABLE 334
CONCERTAI: DEALS, JANUARY 2021− NOVEMBER 2024
TABLE 335
CONCERTAI: OTHER DEVELOPMENTS, JANUARY 2021− NOVEMBER 2024
TABLE 336
AICURE: COMPANY OVERVIEW
TABLE 337
AICURE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 338
AICURE: SERVICE LAUNCHES, JANUARY 2021−NOVEMBER 2024
TABLE 339
AICURE: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 340
MEDIAN TECHNOLOGIES: COMPANY OVERVIEW
TABLE 341
MEDIAN TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 342
LANTERN PHARMA INC.: COMPANY OVERVIEW
TABLE 343
LANTERN PHARMA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 344
LANTERN PHARMA INC.: DEALS, JANUARY 2021−NOVEMBER 2024
TABLE 345
CITELINE, A NORSTELLA COMPANY: COMPANY OVERVIEW
TABLE 346
CITELINE, A NORSTELLA COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 347
CITELINE, A NORSTELLA COMPANY: SOLUTION LAUNCHES, JANUARY 2021− NOVEMBER 2024
TABLE 348
CITELINE, A NORSTELLA COMPANY: DEALS, JANUARY 2021–NOVEMBER 2024
TABLE 349
TRINETX, LLC: COMPANY OVERVIEW
TABLE 350
TRINETX, LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 351
TRINETX, LLC: DEALS, JANUARY 2021−NOVEMBER 2024
TABLE 352
REVIVEMED INC.: COMPANY OVERVIEW
TABLE 353
EURETOS: COMPANY OVERVIEW
TABLE 354
VERISIM LIFE: COMPANY OVERVIEW
TABLE 355
TRIOMICS: COMPANY OVERVIEW
TABLE 356
ARDIGEN: COMPANY OVERVIEW
TABLE 357
QUANTHEALTH LTD.: COMPANY OVERVIEW
TABLE 358
DEEP GENOMICS: COMPANY OVERVIEW
FIGURE 1
AI IN CLINICAL TRIALS MARKET: SEGMENTS CONSIDERED
FIGURE 2
AI IN CLINICAL TRIALS MARKET: YEARS CONSIDERED
FIGURE 3
AI IN CLINICAL TRIALS MARKET: RESEARCH DESIGN
FIGURE 4
AI IN CLINICAL TRIALS MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 5
AI IN CLINICAL TRIALS MARKET: KEY PRIMARY SOURCES
FIGURE 6
AI IN CLINICAL TRIALS MARKET: KEY DATA FROM PRIMARY SOURCES
FIGURE 7
AI IN CLINICAL TRIALS MARKET: KEY INSIGHTS FROM PRIMARIES
FIGURE 8
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 9
MARKET SIZE ESTIMATION: SUPPLY-SIDE REVENUE SHARE ANALYSIS
FIGURE 10
AI IN CLINICAL TRIALS MARKET: TOP-DOWN APPROACH
FIGURE 11
AI IN CLINICAL TRIALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 12
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 13
AI IN CLINICAL TRIALS MARKET: DATA TRIANGULATION
FIGURE 14
AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2024 VS. 2030 (USD MILLION)
FIGURE 15
AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2024 VS. 2030 (USD MILLION)
FIGURE 16
AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2024 VS. 2030 (USD MILLION)
FIGURE 17
AI IN CLINICAL TRIALS MARKET, BY PHASE, 2024 VS. 2030 (USD MILLION)
FIGURE 18
AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION)
FIGURE 19
AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2024 VS. 2030 (USD MILLION)
FIGURE 20
AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2024 VS. 2030 (USD MILLION)
FIGURE 21
AI IN CLINICAL TRIALS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
FIGURE 22
AI IN CLINICAL TRIALS MARKET: REGIONAL SNAPSHOT
FIGURE 23
NEED FOR DATA STANDARDIZATION AND FAVORABLE GOVERNMENT POLICIES TO DRIVE MARKET
FIGURE 24
NORTH AMERICA TO DOMINATE AI IN CLINICAL TRIALS MARKET DURING FORECAST PERIOD
FIGURE 25
US AND PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
FIGURE 26
UK TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
FIGURE 27
DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATES FROM 2024 TO 2029
FIGURE 28
AI IN CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 29
APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2015–2023
FIGURE 30
HEALTHCARE SECURITY BREACHES OF 500+ RECORDS (2009–2023)
FIGURE 31
AI IN CLINICAL TRIALS MARKET: ECOSYSTEM ANALYSIS
FIGURE 32
AI IN CLINICAL TRIALS MARKET: VALUE CHAIN ANALYSIS
FIGURE 33
AI IN CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 34
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
FIGURE 35
KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 36
PATENT PUBLICATION TRENDS IN AI IN CLINICAL TRIALS MARKET, 2015–2024
FIGURE 37
TOP APPLICANTS/OWNERS OF PATENTS AND NUMBER OF PATENTS GRANTED, JANUARY 2015–NOVEMBER 2024
FIGURE 38
AI IN CLINICAL TRIALS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 39
AI IN CLINICAL TRIALS MARKET: FUNDING AND NUMBER OF DEALS, 2022–2024
FIGURE 40
IMPACT OF AI/GEN AI ON AI-BASED CLINICAL TRIAL SOLUTIONS
FIGURE 41
IMPACT OF GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
FIGURE 42
NORTH AMERICA: AI IN CLINICAL TRIALS MARKET SNAPSHOT
FIGURE 43
ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET SNAPSHOT
FIGURE 44
REVENUE ANALYSIS OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET, 2019–2023 (USD BILLION)
FIGURE 45
MARKET SHARE ANALYSIS IN AI IN CLINICAL TRIALS MARKET (2023)
FIGURE 46
RANKING OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET (2023)
FIGURE 47
AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 48
AI IN CLINICAL TRIALS MARKET: COMPANY FOOTPRINT
FIGURE 49
AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 50
EV/EBITDA OF KEY VENDORS
FIGURE 51
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN CLINICAL TRIAL KEY VENDORS
FIGURE 52
AI IN CLINICAL TRIALS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 53
IQVIA INC.: COMPANY SNAPSHOT
FIGURE 54
DASSAULT SYSTÈMES (MEDIDATA): COMPANY SNAPSHOT
FIGURE 55
NVIDIA CORPORATION: COMPANY SNAPSHOT
FIGURE 56
MICROSOFT: COMPANY SNAPSHOT
FIGURE 57
IBM: COMPANY SNAPSHOT
FIGURE 58
MEDIAN TECHNOLOGIES: COMPANY SNAPSHOT
Growth opportunities and latent adjacency in AI in Clinical Trials Market